Introduction
The recently published analysis of the Nurses' Health Study [1 ] in the scientific literature and public media sheds a new perspective on the importance of ovarian hormones in overall survival and general health. The latest information once again brings up the longstanding controversy of hormonal replacement therapy (HRT) in menopausal women and these data are also of importance to gynecologic cancer survivors.
That preservation of ovarian function is associated with a lower risk of coronary heart disease (CHD) is well known [2] [3] [4] [5] . In the mid-1990s, many observational studies and meta-analyses advocated that HRT reduced the risk of CHD by up to 50% [6] [7] [8] [9] , due to the beneficial effects of estrogens on serum lipids and endothelial function [10] . As CHD is a leading cause of death in postmenopausal women in the United States, HRT was the second most frequently prescribed medication in 2000, with approximately 38% of postmenopausal women using it [11] .
Since the publication of the Women's Health Initiative (WHI) results in July 2002, 77% fewer women start HRT at the menopause [12] . Unfortunately, the WHI failed to address the short-term risks and benefits of HRT administered for the alleviation of menopausal symptoms, which is the most important indication for therapy in the majority of patients. The study did not focus on the issue of quality of life in postmenopausal women, neither in the combination HRT arm nor in the later publication on the estrogen therapy-alone arm.
At the time of writing this review, the latest cohort study of the Nurses' Health Study was published. The study compared healthy women with and without ovarian conservation at hysterectomy for benign disease during 24 years of follow-up. The primary finding was that oophorectomy increased the risk of death from any cause [hazard ratio ¼ 1.12, 95% confidence interval (CI) 1.03-1.21]. More importantly, when excluding women who had used estrogen therapy, the age-adjusted risk of all-cause death from oophorectomy was higher (hazard ratio 1.28, 95%
Purpose of review As the length of survival in patients with gynecological malignancies increases due to advances in early diagnosis and therapy, quality of life becomes a major issue for the survivors. These women frequently suffer symptoms following an iatrogenically induced menopause. Many gynecologists advise these patients against hormonal replacement therapy. This review attempts to provide the clinician with information based on current evidence.
Recent findings
The most recent two prospective studies did not find an increase in the recurrence rates in endometrial cancer patients who used hormonal replacement therapy. To date, there are few studies on hormonal replacement therapy in patients with ovarian cancer but the available data suggest that there is no detriment to overall or disease-free survival. There are no data showing an association between poorer outcome and hormonal replacement therapy use in patients with cervical or vulvar cancers. Summary There is no evidence showing hormones negatively influence survival after treatment for epithelial ovarian, squamous cervical or vulvar cancer. Their use can be considered in symptomatic patients with endometrial cancer, after weighing the benefits against the risk of recurrence. Gynecologic cancer survivors suffering from menopausal symptoms should be supported by advice about the alternatives to hormonal replacement therapy and by giving them nonbiased information on the present knowledge on the effects of hormonal use in women with a previous cancer. It is reasonable to prescribe hormonal replacement therapy to symptomatic, well informed patients. CI 1.01-1.62 versus hazard ratio 1.1, 95% 1.03-1.18 when including women with estrogen therapy). This difference was even more noteworthy in women who had undergone surgery when they were younger than 50 years old (hazard ratio 1.54, 95% CI 1.17-2.02 versus hazard ratio 1.18, 95% CI 1.07-1.3 when including women with estrogen therapy).
The incidence of stroke was significantly higher in oophorectomized women only when those who had used estrogen therapy were excluded (hazard ratio 1.85, 95% CI 1.09-3. 16 versus not significant when including women with estrogen therapy). This observation was even more pronounced in women who had undergone surgery when they were younger than 50 years old (hazard ratio 2.19, 95% CI 1.16-4.14 versus not significant when including women with estrogen therapy). Similarly, the incidence of CHD was significantly higher in oophorectomized women who had undergone surgery at a young age only when those who had used estrogen therapy were excluded from the multivariate analysis (hazard ratio 1.98, 95% CI 1.18-3.32 versus not significant when including women with estrogen therapy). These lately released findings suggest that estrogen therapy may protect oophorectomized women from the risks of CHD, stroke and all-cause death.
The use of HRT in gynecological cancer survivors is hotly debated and many primary care gynecologists and even gynecologic oncologists, advise these women against it. As the length of survival increases due to advances in early diagnosis and effective therapy, quality of life becomes a major issue for many of our patients. These women frequently complain of severe symptoms following an iatrogenically induced premature menopause.
In a publication of the American College of Obstetricians and Gynecologists Committee of Gynecologic Practice in 2000 [13] , the members stated that 'the decision to use HRT in gynecological cancer patients should be individualized on the basis of potential benefit and risk to the patient'. In 2005, Creasman [14] thoroughly reviewed 'hormonal therapy after cancers'. He concluded that there seems to be little (if any) risk in giving HRT to women who have had breast or endometrial cancer, and that there are no data to suggest that HRT is contraindicated in women who have been treated for cervical or ovarian cancer.
In recent years, there has been a paucity of novel information on this topic. The dramatic decrease in the use of HRT since 2002 in healthy women is even more marked in women who have already been treated for gynecological cancer. The purpose of this review is to provide the clinician with information based on current evidence, which may assist in the management of gynecological cancer survivors who suffer from menopausal symptoms.
In addition to our attempt to assess the relative risk of recurrence, we will explore alternative treatments. Due to the unwillingness of clinicians and women to use HRT, there is difficulty in performing new clinical trials in this area. Therefore, it is unlikely that there will be a new evidence base in the near future.
Endometrial cancer
Endometrial adenocarcinoma is primarily a disease of postmenopausal women; however, 25% of cases occur in premenopausal patients and 5% in women under the age of 40 years [15, 16] . As a consequence, there is a large group of women that experience a surgically induced menopause due to endometrial cancer and many suffer from menopausal symptoms. Quality of life after treatment becomes a major issue particularly as the prognosis of this disease is favorable.
Whereas it is well accepted that unopposed estrogen plays a significant role in endometrial carcinogenesis [17] , the role of estrogens in cancer propagation is less clear. Several retrospective studies have addressed this issue but none has revealed an increase in recurrence or death rate for women taking estrogen therapy after treatment for endometrial cancer [18] [19] [20] . Although these studies are limited by their small sample size, short follow-up and retrospective trial design, none concluded with the contention that estrogen therapy was dangerous for this group of patients. Nevertheless, women with a history of endometrial carcinoma were usually denied this therapy because adenocarcinoma of the endometrium is considered an estrogendependent neoplasm and administration of estrogen might theoretically stimulate occult disease.
In 2004, Levgur [21] reviewed the four existing casecontrol studies; of the 228 patients who received estrogen therapy, 3.5% developed recurrences as opposed to 16.5% among the 309 women receiving no therapy. The author concluded that administration of estrogen therapy at an early stage of disease is therefore well tolerated and appropriate.
Since 2005, only two prospective trials have been conducted to test the hypothesis that estrogen therapy has a deleterious effect on the risk of recurrence in patients with endometrial cancer.
(1) In a prospective case-control study ( That other uterine cancers, such as endometrial stromal sarcoma, are probably hormone-dependent should be mentioned, and the use of HRT in these patients must be addressed individually.
Epithelial ovarian cancer
Although the median age of diagnosis of ovarian cancer is 63, there is a significant proportion of premenopausal women suffering from this disease [24] . Since most of these malignancies are discovered at advanced stages, long-term prevention of disease recurrence may not be of great significance, whereas quality of life is of major importance.
There is no conclusive evidence that HRT promotes epithelial ovarian cancer. No data support the hypothesis that estrogen might stimulate quiescent ovarian cancer cells, or that hormonal receptors have a clinical role in this disease. There are few studies on the use of HRT in patients with ovarian cancer. To date, there are only two retrospective cohort studies [25, 26] and one randomized controlled trial (RCT) [27] . In these studies, there are no reported differences in overall or disease-free survival in patients treated in comparison with control individuals.
Until more evidence becomes available, the current overall consensus is that HRT is acceptable for ovarian cancer patients who exhibit troublesome menopausal symptomatology. Further studies are needed to clearly delineate specific contraindications. The histologic type of the tumor may be an important factor to consider prior to the initiation of such therapy. Nonepithelial ovarian cancers are more common in young women, and the issue of HRT is more imperative in these patients. An individualized approach is encouraged in these cases.
Cervical cancer
Although estrogen receptors have been found in squamous cervical cancer tissue, it is not considered an estrogen-responsive tumor. An association between HRT and this tumor type has never been shown.
The study by Ploch [28] reported on 120 women who received HRT after treatment for stage I/II cervical cancer and showed no change in survival or disease-free interval at 5 years. HRT after treatment for cervical cancer is used quite frequently by gynecological oncologists.
A rise in the proportion of patients with adenocarcinoma of the cervix [29] has been described. Use of estrogen therapy was associated with a RR of 2.7 (95% CI 1.1-6.8) for adenocarcinoma [30] but there is currently no study on recurrence risk in survivors of adenocarcinoma of the cervix. It has been suggested that the approach to advice about HRT should be the same as that for endometrial adenocarcinoma [31] .
Vulvar and vaginal cancer
There are no data showing an association between outcome for these cancers and use of HRT. Therefore, HRT is not contraindicated in women treated for vulvar or vaginal cancer.
Alternatives to estrogen for menopausal symptoms
Vasomotor symptoms are the main cause of suffering in women undergoing iatrogenically induced menopause and since the WHI results these symptoms have remained virtually the only indication for HRT.
The results from the WHI provided data only for oral HRT and therefore other routes of administration might be safer, such as transdermal or vaginally delivered estrogens.
Tibolone, a steroidogenic compound with both estrogenic and progestagenic properties, is efficient in controlling both vasomotor symptoms [32] and osteoporosis [33] . In a case-control study of almost 400 endometrial cancer survivors [34] , there was no evidence that tibolone had adverse effects on disease-free or overall survival. The authors concluded that tibolone could be used in these patients.
Many nonestrogen substances have been studied for their effectiveness in alleviating vasomotor symptoms. Some of these therapies such as nonpharmacologic and complementary alternative medicine therapies [35] give similar effects to placebo which in itself improves symptoms in about 25% of women. Placebo-controlled studies show that placebo can give better results than progestins such as megestrol acetate [36, 37] .
Centrally acting agents such as the selective serotonine re-uptake inhibitors (SSRIs), for example venlafaxine [38] and fluoxetine [39] , and the antiseizure agent gabapentin, have shown clinical effectiveness and appear to be reasonably well tolerated. SSRIs and gabapentin are well tolerated with regard to tumor proliferation and provide good control of vasomotor symptoms, with only minor side-effects. They are regarded as the most promising nonhormonal treatments for hot flashes in breast cancer survivors [35] and their use certainly could be considered in other cancer survivors.
We have focused on treatment of vasomotor symptoms but there are also alternatives to HRT for the prevention of osteoporosis and cardiovascular diseases. The first step to achieve this should be to adopt a correct life style [40] , followed by diphosphonates [41] , raloxifen [42] , and statins [43] which have all proven effective.
Conclusion
Surgically induced menopausal symptoms are usually more severe and may last longer than those resulting from a natural menopause. Patients' quality of life may be severely affected and hormones are very effective in relieving them. Women need to be made aware of the available data and not be given only unsubstantiated biased opinion. It is still a controversial issue whether the patient with a history of a gynecologic malignancy can be safely prescribed HRT. This issue has not been extensively studied, and evidence-based conclusions cannot be drawn from available data. SSRIs and gabapentin are well tolerated with regard to tumor proliferation and are currently the most promising alternative to HRT for vasomotor symptoms.
Squamous cell cancers of the cervix, vulva and vagina are unlikely to be influenced by HRT. No evidence exists to show that HRT negatively influences survival after treatment for ovarian cancer. It is imperative to provide assistance to patients suffering from menopausal symptoms. This can be done both by offering them alternatives to HRT and by giving them nonbiased information on the present knowledge on the effects of HRT use in women with previous cancer. It is reasonable to prescribe HRT to selected, symptomatic, well informed patients.
Antagonism to the use of HRT in endometrial cancer survivors has been very strong, although there has been a lack of data to support this view. The data presented suggest that HRT can be given without detrimental effects, mainly on the basis of retrospective, case-controlled or cohort-controlled studies. The only prospective randomized double-blind study in patients with endometrial cancer was halted as a result of the impact of the WHI study. However, existing data do not suggest an increased risk of cancer recurrence with HRT usage. Therefore, on the basis of the currently available evidence, HRT can be considered in the symptomatic patient after surgical treatment, after weighing the benefits against the theoretical risk of recurrence.
